T-C Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7958218/publications.pdf

Version: 2024-02-01

197 papers	9,970 citations	23567 58 h-index	49909 87 g-index
201 all docs	201 docs citations	201 times ranked	8622 citing authors

#	Article	IF	Citations
1	Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice. MBio, 2022, 13, e0325221.	4.1	4
2	Control of Tumors by Antigen-Specific CD8+ T Cells through PDL1-Targeted Delivery of Antigenic Peptide. Journal of Immunology Research, 2022, 2022, 1-8.	2.2	0
3	Erratum for Peng et al., â€œDevelopment of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Miceâ€• MBio, 2022, , e0029622.	4.1	0
4	Albumin and interferon-Î² fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. , 2022, 10, e004342.		8
5	PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunology, Immunotherapy, 2021, 70, 1049-1062.	4.2	17
6	Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. MBio, 2021, 12, .	4.1	41
7	Cervical Cancer Immunotherapy: Facts and Hopes. Clinical Cancer Research, 2021, 27, 4953-4973.	7.0	129
8	Development of a Novel Mouse Model of Spontaneous High-Risk HPVE6/E7â€“Expressing Carcinoma in the Cervicovaginal Tract. Cancer Research, 2021, 81, 4560-4569.	0.9	11
9	Control of Spontaneous HPV16 E6/E7 Expressing Oral Cancer in HLA-A2 (AAD) Transgenic Mice with Therapeutic HPV DNA Vaccine. Journal of Biomedical Science, 2021, 28, 63.	7.0	8
10	Vaccination Strategies for the Control and Treatment of HPV Infection and HPV-Associated Cancer. Recent Results in Cancer Research, 2021, 217, 157-195.	1.8	20
11	Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells. Frontiers in Immunology, 2021, 12, 755995.	4.8	3
12	Interleukin 2-Based Fusion Proteins for the Treatment of Cancer. Journal of Immunology Research, 2021, 2021, 1-11.	2.2	12
13	Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of Biomedical Science, 2020, 27, 104.	7.0	287
14	CORONAVIRUS VACCINE DEVELOPMENT: FROM SARS AND MERS TO COVID-19 (RUSSIAN TRANSLATION). Juvenis Scientia, 2020, 6, 41-80.	0.2	0
15	Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines. Journal of Biomedical Science, 2019, 26, 41.	7.0	8
16	Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics. Clinical Cancer Research, 2019, 25, 4516-4529.	7.0	22
17	Programmed self-assembly of peptideâ€“major histocompatibility complex for antigen-specific immune modulation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4032-E4040.	7.1	7
18	Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control. Cancer Immunology Research, 2018, 6, 305-319.	3.4	10

#	Article	IF	Citations
19	Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. Human Gene Therapy, 2018, 29, 971-996.	2.7	44
20	Integrating chemical and mechanical signals through dynamic coupling between cellular protrusions and pulsed ERK activation. Nature Communications, 2018, 9, 4673.	12.8	48
21	Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination. Virology, 2018, 525, 205-215.	2.4	6
22	Intramuscular vaccination targeting mucosal tumor draining lymph node enhances integrins-mediated CD8+ T cell infiltration to control mucosal tumor growth. OncoImmunology, 2018, 7, e1463946.	4.6	4
23	A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells. OncoImmunology, 2018, 7, e1472187.	4.6	12
24	Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. Gene Therapy, 2017, 24, 408-415.	4.5	13
25	Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model. Vaccine, 2017, 35, 3850-3858.	3.8	10
26	The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Research, 2017, 231, 148-165.	2.2	46
27	Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus. Cell and Bioscience, 2017, 7, 46.	4.8	8
28	Annexin A5 Increases Survival in Murine Sepsis Model by Inhibiting HMGB1-Mediated Proinflammation and Coagulation. Molecular Medicine, 2016, 22, 424-436.	4.4	27
29	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. Journal of Gynecologic Oncology, 2016, 27, e51.	2.2	99
30	Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo. Antimicrobial Agents and Chemotherapy, 2016, 60, 6460-6470.	3.2	41
31	Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease. Cell and Bioscience, 2016, 6, 16.	4.8	19
32	Buccal injection of synthetic HPV long peptide vaccine induces local and systemic antigen-specific CD8+ T-cell immune responses and antitumor effects without adjuvant. Cell and Bioscience, 2016, 6, 17.	4.8	15
33	A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecologic Oncology, 2016, 140, 245-252.	1.4	90
34	Current state in the development of candidate therapeutic HPV vaccines. Expert Review of Vaccines, 2016, 15, 989-1007.	4.4	90
35	Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cellâ€"Mediated Tumor Control in the Genital Tract. Clinical Cancer Research, 2016, 22, 657-669.	7.0	71
36	Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer. PLoS ONE, 2015, 10, e116389.	2.5	20

#	Article	IF	Citations
37	Gain of HIF-1Î± under Normoxia in Cancer Mediates Immune Adaptation through the AKT/ERK and VEGFA Axes. Clinical Cancer Research, 2015, 21, 1438-1446.	7.0	46
38	Local administration of granulocyte macrophage colony-stimulating factor induces local accumulation of dendritic cells and antigen-specific CD8+ T cells and enhances dendritic cell cross-presentation. Vaccine, 2015, 33, 1549-1555.	3.8	22
39	Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Therapy, 2015, 22, 528-535.	4.5	22
40	Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell and Bioscience, 2015, 5, 35.	4.8	16
41	Nanoparticle-induced intraperitoneal hyperthermia and targeted photoablation in treating ovarian cancer. Oncotarget, 2015, 6, 26861-26875.	1.8	21
42	Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4. Oncotarget, 2015, 6, 27751-27762.	1.8	22
43	Direct T Cell Activation via CD40 Ligand Generates High Avidity CD8+ T Cells Capable of Breaking Immunological Tolerance for the Control of Tumors. PLoS ONE, 2014, 9, e93162.	2.5	20
44	Cancer Therapy: Vaginal Delivery of Paclitaxel via Nanoparticles with Nonâ€Mucoadhesive Surfaces Suppresses Cervical Tumor Growth (Adv. Healthcare Mater. 7/2014). Advanced Healthcare Materials, 2014, 3, 1120-1120.	7.6	0
45	Enhanced Cancer Radiotherapy through Immunosuppressive Stromal Cell Destruction in Tumors. Clinical Cancer Research, 2014, 20, 644-657.	7.0	49
46	Immune-mediated tumor evolution: Nanog links the emergence of a stem like cancer cell state and immune evasion. OncoImmunology, 2014, 3, e947871.	4.6	21
47	Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis. Current Obstetrics and Gynecology Reports, 2014, 3, 18-32.	0.8	9
48	Enhancement of Tumor-Specific T Cellâ€“Mediated Immunity in Dendritic Cellâ€“Based Vaccines by Mycobacterium tuberculosis Heat Shock Protein X. Journal of Immunology, 2014, 193, 1233-1245.	0.8	34
49	Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell and Bioscience, 2014, 4, 11.	4.8	33
50	Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model. Drug Delivery and Translational Research, 2014, 4, 203-209.	5.8	12
51	Cancer immunotherapy using a potent immunodominant CTL epitope. Vaccine, 2014, 32, 6039-6048.	3.8	5
52	Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNI³. Clinical Cancer Research, 2014, 20, 5456-5467.	7.0	49
53	Sequential treatment of HPV E6 and E7-expressing TC-1 cells with bortezomib and celecoxib promotes apoptosis through p-p38 MAPK-mediated downregulation of cyclin D1 and CDK2. Oncology Reports, 2014, 31, 2429-2437.	2.6	16
54	Control of HPV Infection and Related Cancer Through Vaccination. Recent Results in Cancer Research, 2014, 193, 149-171.	1.8	31

#	Article	IF	Citations
55	Cancer Immunotherapy Employing an Innovative Strategy to Enhance CD4+ T Cell Help in the Tumor Microenvironment. PLoS ONE, 2014, 9, e115711.	2.5	14
56	Histone deacetylase inhibitor AR-42 enhances E7-specific CD8+ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Molecular Medicine, 2013, 91, 1221-1231.	3.9	23
57	Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunology, Immunotherapy, 2013, 62, 1175-1185.	4.2	35
58	Targeted Coating With Antigenic Peptide Renders Tumor Cells Susceptible to CD8+ T Cell-mediated Killing. Molecular Therapy, 2013, 21, 542-553.	8.2	16
59	Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunology, Immunotherapy, 2013, 62, 171-182.	4.2	63
60	Mucosal Imprinting of Vaccine-Induced CD8 ⁺ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine, 2013, 5, 172ra20.	12.4	195
61	Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells. Pharmacological Research, 2013, 71, 23-33.	7.1	12
62	Innovative DNA Vaccine to Break Immune Tolerance Against Tumor Self-Antigen. Human Gene Therapy, 2013, 24, 181-188.	2.7	13
63	Creation of a Merkel cell polyomavirus small T antigen-expressing murine tumor model and a DNA vaccine targeting small T antigen. Cell and Bioscience, 2013, 3, 29.	4.8	32
64	Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity. Cancer Research, 2013, 73, 2493-2504.	0.9	90
65	Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide. Cell and Bioscience, 2013, 3, 48.	4.8	6
66	Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53. PLoS ONE, 2013, 8, e56912.	2.5	25
67	Immune Mechanism of the Antitumor Effects Generated by Bortezomib. Journal of Immunology, 2012, 189, 3209-3220.	0.8	71
68	LAH4 enhances CD8+ T cell immunity of protein/peptide-based vaccines. Vaccine, 2012, 30, 784-793.	3.8	42
69	Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine, 2012, 30, 1322-1329.	3.8	54
70	Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen. Cell and Bioscience, 2012, 2, 36.	4.8	25
71	Emerging human papillomavirus vaccines. Expert Opinion on Emerging Drugs, 2012, 17, 469-492.	2.4	62
72	Ovarian Cancer Gene Therapy Using HPV-16 Pseudovirion Carrying the HSV-tk Gene. PLoS ONE, 2012, 7, e40983.	2.5	14

#	Article	IF	Citations
73	Cancer Vaccination Drives Nanog-Dependent Evolution of Tumor Cells toward an Immune-Resistant and Stem-like Phenotype. Cancer Research, 2012, 72, 1717-1727.	0.9	72
74	Tumor-Targeted Delivery of IL-2 by NKG2D Leads to Accumulation of Antigen-Specific CD8+ T Cells in the Tumor Loci and Enhanced Anti-Tumor Effects. PLoS ONE, 2012, 7, e35141.	2.5	36
75	Strategies to Improve DNA Vaccine Potency: HPV-Associated Cervical Cancer as a Model System. , 2012, , 37-65.		0
76	Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection. Vaccine, 2011, 29, 1082-1089.	3.8	20
77	DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell and Bioscience, 2011, 1, 26.	4.8	6
78	In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell and Bioscience, 2011, 1, 3.	4.8	23
79	Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines. Journal of Biomedical Science, 2011, 18, 21.	7.0	24
80	HPV pseudovirions as DNA delivery vehicles. Therapeutic Delivery, 2011, 2, 427-430.	2.2	11
81	Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents. Human Gene Therapy, 2011, 22, 809-819.	2.7	33
82	Molecular Pathogenesis, Detection and Clinical Management of Pre-invasive Cervical Lesions. , 2011, , 437-466.		0
83	HPV and Therapeutic Vaccines: Where are We in 2010?. Current Cancer Therapy Reviews, 2010, 6, 81-103.	0.3	36
84	Therapeutic HPV DNA vaccines. Immunologic Research, 2010, 47, 86-112.	2.9	107
85	Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Biomedical Science, 2010, 17, 32.	7.0	40
86	Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation. Journal of Biomedical Science, 2010, 17, 88.	7.0	92
87	Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA. Gene Therapy, 2010, 17, 531-540.	4.5	10
88	Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Therapy, 2010, 17, 1453-1464.	4.5	26
89	Ectopic Expression of X-Linked Lymphocyte-Regulated Protein pM1 Renders Tumor Cells Resistant to Antitumor Immunity. Cancer Research, 2010, 70, 3062-3070.	0.9	21
90	Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific Immunotherapy. Molecular Therapy, 2010, 18, 692-699.	8.2	53

#	Article	IF	Citations
91	Carrageenan as an adjuvant to enhance peptide-based vaccine potency. Vaccine, 2010, 28, 5212-5219.	3.8	49
92	DNA vaccine with Î±-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells. Vaccine, 2010, 28, 7297-7305.	3.8	38
93	Perspectives for Preventive and Therapeutic HPV Vaccines. Journal of the Formosan Medical Association, 2010, 109, 4-24.	1.7	96
94	Current Status of Human Papillomavirus Vaccines. Journal of the Formosan Medical Association, 2010, 109, 481-483.	1.7	17
95	Immunotherapy for Cervical Cancer. BioDrugs, 2010, 24, 109-129.	4.6	92
96	DNA vaccines for cervical cancer. American Journal of Translational Research (discontinued), 2010, 2, 75-87.	0.0	16
97	Activation of Akt as a Mechanism for Tumor Immune Evasion. Molecular Therapy, 2009, 17, 439-447.	8.2	80
98	A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3. Clinical Cancer Research, 2009, 15, 361-367.	7.0	186
99	Expression of ILâ€15RA or an ILâ€15/ILâ€15RA fusion on CD8⁺ T cells modifies adoptively transferred Tâ€cell function in cis. European Journal of Immunology, 2009, 39, 491-506.	2.9	59
100	Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunology, Immunotherapy, 2009, 58, 737-748.	4.2	59
101	Femtosecond laser treatment enhances DNA transfection efficiency in vivo. Journal of Biomedical Science, 2009, 16, 36.	7.0	26
102	Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine, 2009, 27, 5450-5459.	3.8	114
103	Therapeutic HPV DNA vaccines. Expert Review of Vaccines, 2009, 8, 1221-1235.	4.4	45
104	Treatment With Cyclooxygenase-2 Inhibitors Enables Repeated Administration of Vaccinia Virus for Control of Ovarian Cancer. Molecular Therapy, 2009, 17, 1365-1372.	8.2	43
105	Modification of Dendritic Cells to Enhance Cancer Vaccine Potency. , 2009, , 133-157.		0
106	Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Journal of Molecular Medicine, 2008, 86, 899-908.	3.9	34
107	Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Therapy, 2008, 15, 1156-1166.	4.5	26
108	Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice. Gene Therapy, 2008, 15, 1176-1183.	4.5	12

#	Article	IF	Citations
109	Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses. Gene Therapy, 2008, 15, 677-687.	4.5	29
110	Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine, 2008, 26, 351-360.	3.8	56
111	Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine, 2008, 26, 4314-4319.	3.8	19
112	Molecular Epidemiology of Human Papillomavirus. Journal of the Formosan Medical Association, 2008, 107, 198-217.	1.7	68
113	RNA Interference-MediatedIn VivoSilencing of Fas Ligand as a Strategy for the Enhancement of DNA Vaccine Potency. Human Gene Therapy, 2008, 19, 763-773.	2.7	32
114	Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opinion on Biological Therapy, 2008, 8, 421-439.	3.1	156
115	Enhancement of Antibody Responses toBacillus anthracisProtective Antigen Domain IV by Use of Calreticulin as a Chimeric Molecular Adjuvant. Infection and Immunity, 2008, 76, 1952-1959.	2.2	42
116	Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cellâ€“Mediated Antitumor Immunity Induced by DNA Vaccination. Clinical Cancer Research, 2008, 14, 3185-3192.	7.0	143
117	Inhibition of Tumor Growth by NK1.1+ Cells and CD8+ T Cells Activated by IL-15 through Receptor Î²/Common Î³ Signaling in trans. Journal of Immunology, 2008, 181, 8237-8247.	0.8	27
118	Enhancement of DNA Vaccine Potency through Coadministration of CIITA DNA with DNA Vaccines via Gene Gun. Journal of Immunology, 2008, 180, 7019-7027.	0.8	43
119	Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Review of Vaccines, 2007, 6, 227-239.	4.4	63
120	DNA vaccines for cervical cancer: from bench to bedside. Experimental and Molecular Medicine, 2007, 39, 679-689.	7.7	68
121	Opportunities to Improve the Prevention and Treatment of Cervical Cancer. Current Molecular Medicine, 2007, 7, 490-503.	1.3	29
122	DNA Vaccines Encoding Ii-PADRE Generates Potent PADRE-specific CD4+ T-Cell Immune Responses and Enhances Vaccine Potency. Molecular Therapy, 2007, 15, 1211-1219.	8.2	75
123	Monitoring the Trafficking of Adoptively Transferred Antigen- Specific CD8-Positive T Cells In Vivo, Using Noninvasive Luminescence Imaging. Human Gene Therapy, 2007, 18, 575-588.	2.7	43
124	Epigallocatechin-3-Gallate Enhances CD8+ T Cellâ€“Mediated Antitumor Immunity Induced by DNA Vaccination. Cancer Research, 2007, 67, 802-811.	0.9	110
125	Ectopic Expression of Vascular Cell Adhesion Molecule-1 as a New Mechanism for Tumor Immune Evasion. Cancer Research, 2007, 67, 1832-1841.	0.9	81
126	Cancer Immunotherapy Using Irradiated Tumor Cells Secreting Heat Shock Protein 70. Cancer Research, 2007, 67, 10047-10057.	0.9	26

#	Article	IF	Citations
127	A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine, 2007, 25, 127-135.	3.8	57
128	Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine, 2007, 25, 7824-7831.	3.8	34
129	The Role of Vascular Cell Adhesion Molecule-1 in Tumor Immune Evasion. Cancer Research, 2007, 67, 6003-6006.	0.9	98
130	Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life and Intracellular Targeting Strategies with a Strategy to Boost CD4⁺ T Cells. Human Gene Therapy, 2007, 18, 1129-1140.	2.7	30
131	Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. International Journal of Cancer, 2007, 120, 1696-1703.	5.1	38
132	Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. European Journal of Immunology, 2007, 37, 310-314.	2.9	25
133	Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer, 2007, 110, 420-431.	4.1	20
134	Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Therapy, 2007, 14, 20-29.	4.5	46
135	Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Therapy, 2007, 14, 921-929.	4.5	49
136	Control of human mesothelin-expressing tumors by DNA vaccines. Gene Therapy, 2007, 14, 1189-1198.	4.5	41
137	Immunotherapeutic strategies employing RNA interference technology for the control of cancers. Journal of Biomedical Science, 2007, 14, 15-29.	7.0	20
138	Prevention and Treatment of Cervical Cancer by Vaccination. , 2007, , 125-154.		1
139	Preventive and therapeutic HPV vaccines. Current Opinion in Investigational Drugs, 2007, 8, 1038-50.	2.3	9
140	How will HPV vaccines affect cervical cancer?. Nature Reviews Cancer, 2006, 6, 753-763.	28.4	237
141	Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Therapy, 2006, 13, 873-885.	4.6	27
142	Characterization of HLA-A2-restricted HPV-16 E7-specific CD8+ T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Therapy, 2006, 13, 67-77.	4.5	47
143	A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Therapy, 2006, 13, 257-265.	4.5	44
144	Prospects of RNA interference therapy for cancer. Gene Therapy, 2006, 13, 464-477.	4.5	322

#	Article	IF	Citations
145	Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunology Letters, 2006, 106, 126-134.	2.5	42
146	Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma. Clinical Cancer Research, 2006, 12, 827-831.	7.0	81
147	Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. Journal of Biomedical Science, 2005, 12, 689-700.	7.0	34
148	DNA Vaccines Employing Intracellular Targeting Strategies and a Strategy to Prolong Dendritic Cell Life Generate a Higher Number of CD8+ Memory T Cells and Better Long-Term Antitumor Effects Compared with a DNA Primeâ€“Vaccinia Boost Regimen. Human Gene Therapy, 2005, 16, 26-34.	2.7	21
149	Vaccination with Dendritic Cells Transfected with BAK and BAX siRNA Enhances Antigen-Specific Immune Responses by Prolonging Dendritic Cell Life. Human Gene Therapy, 2005, 16, 584-593.	2.7	64
150	Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine, 2005, 23, 3864-3874.	3.8	28
151	Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Therapy, 2005, 12, 1180-1186.	4.5	81
152	Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Research, 2005, 65, 309-16.	0.9	79
153	Vaccination with a DNA Vaccine Encoding Herpes Simplex Virus Type 1 VP22 Linked to Antigen Generates Long-Term Antigen-Specific CD8-Positive Memory T Cells and Protective Immunity. Human Gene Therapy, 2004, 15, 167-177.	2.7	61
154	Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 2004, 78, 4638-4645.	3.4	164
155	Enhancement of DNA Vaccine Potency by Coadministration of a Tumor Antigen Gene and DNA Encoding Serine Protease Inhibitor-6. Cancer Research, 2004, 64, 400-405.	0.9	58
156	Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6. Journal of Virology, 2004, 78, 8468-8476.	3.4	116
157	Enhancement of suicidal DNA vaccine potency by delaying suicidal DNA-induced cell death. Gene Therapy, 2004, 11, 336-342.	4.5	45
158	Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Therapy, 2004, 11, 1011-1018.	4.5	104
159	Focus on endometrial and cervical cancer. Cancer Cell, 2004, 5, 533-538.	16.8	99
160	A DNA vaccine co-expressing antigen and an anti-apoptotic molecule further enhances the antigen-specific CD8+ T-cell immune response. Journal of Biomedical Science, 2004, 11, 493-499.	7.0	28
161	Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways. European Journal of Immunology, 2004, 34, 1892-1900.	2.9	14
162	Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine, 2004, 22, 3993-4001.	3.8	58

#	Article	IF	Citations
163	Vaccination to prevent and treat cervical cancer. Human Pathology, 2004, 35, 971-982.	2.0	102
164	Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Current Opinion in Investigational Drugs, 2004, 5, 1247-61.	2.3	14
165	CD8+ T cells, NK cells and IFN-Î³ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Therapy, 2003, 10, 1311-1320.	4.5	54
166	Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine, 2003, 21, 4036-4042.	3.8	164
167	Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles. Molecular Therapy, 2003, 8, 559-566.	8.2	43
168	Preventative and therapeutic vaccines for cervical cancer. Expert Review of Vaccines, 2003, 2, 495-516.	4.4	38
169	Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies. Journal of Immunology, 2003, 171, 2970-2976.	0.8	87
170	D<scp>evelopment of</scp> HPV V<scp>accines for</scp> HPV<scp>-associated</scp> H<scp>ead and</scp> N<scp>eck</scp> S<scp>quamous</scp> C<scp>ell</scp> C<scp>arcinoma</scp>. Critical Reviews in Oral Biology and Medicine, 2003, 14, 345-362.	4.4	62
171	HPV DNA vaccines. Frontiers in Bioscience - Landmark, 2003, 8, d55-68.	3.0	30
172	Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. Journal of Clinical Investigation, 2003, 112, 109-117.	8.2	73
173	Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. Journal of Clinical Investigation, 2003, 112, 109-117.	8.2	142
174	Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Research, 2003, 63, 2393-8.	0.9	52
175	DNA vaccines for cancer. IDrugs: the Investigational Drugs Journal, 2003, 6, 1155-64.	0.7	9
176	Improving DNA Vaccine Potency by Linking Marek's Disease Virus Type 1 VP22 to an Antigen. Journal of Virology, 2002, 76, 2676-2682.	3.4	83
177	Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22â€“Antigen Fusion. Human Gene Therapy, 2002, 13, 553-568.	2.7	110
178	Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. Journal of Biomedical Science, 2002, 9, 675-687.	7.0	25
179	Repeated DNA Vaccinations Elicited Qualitatively Different Cytotoxic T Lymphocytes and Improved Protective Antitumor Effects. Journal of Biomedical Science, 2002, 9, 675-687.	7.0	11
180	Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Therapy, 2001, 8, 128-138.	4.5	25

#	Article	IF	Citations
181	Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Therapy, 2001, 8, 376-383.	4.5	104
182	Improving Vaccine Potency Through Intercellular Spreading and Enhanced MHC Class I Presentation of Antigen. Journal of Immunology, 2001, 166, 5733-5740.	0.8	140
183	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Targeting Antigen to Endosomal/Lysosomal Compartments. Human Gene Therapy, 2001, 12, 235-252.	2.7	72
184	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage ofMycobacterium tuberculosisHeat Shock Protein 70 Gene to an Antigen Gene. Journal of Immunology, 2001, 166, 6218-6226.	0.8	61
185	Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen. Journal of Virology, 2001, 75, 2368-2376.	3.4	80
186	Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. Journal of Clinical Investigation, 2001, 108, 669-678.	8.2	225
187	Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. , 2000, 86, 725-730.		64
188	Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-GuÃ©rin (BCG) hsp65 and HPV16 E7. Clinical and Experimental Immunology, 2000, 121, 216-225.	2.6	161
189	Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Therapy, 2000, 7, 726-733.	4.5	110
190	Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine, 2000, 18, 2015-2022.	3.8	81
191	Antigen-specific immunotherapy for human papillomavirus 16 E7-expressing tumors grown in the liver. Journal of Hepatology, 2000, 33, 91-98.	3.7	19
192	Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Therapy, 1999, 6, 1972-1981.	4.5	77
193	Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. , 1998, 78, 41-45.		116
194	Antigenâ€specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. International Journal of Cancer, 1998, 78, 41-45.	5.1	3
195	Coinfection of HPV-11 and HPV-16 in a Case of Laryngeal Squamous Papillomas With Severe Dysplasia. Laryngoscope, 1997, 107, 942-947.	2.0	25
196	Detection of the human cytomegalovirus 2.0-kb immediate early gene 1 transcripts in permissive and nonpermissive infections by RNA in situ hybridization. Journal of Biomedical Science, 1997, 4, 19-27.	7.0	4
197	Localization of epstein-barr virus-encoded small RNA-1 by in situ reverse transcription: Demonstration of cDNA generation in formalin-fixed paraffin-embedded tissue sections. Journal of Biomedical Science, 1995, 2, 249-255.	7.0	0